

//
//

()

/

*

(ADHD) / :

mg/d mg/d (/ ± /)
ADHD

ADHD

ADHD

ADHD

()

Attention Deficit /

(ADHD) Hyperactivity Disorder

()

ADHD

() ()

%

ADHD

()

E-mail: farabgol@sbmu.ac.ir

()

ADHD

() Mozes

Hyperkinetic

(HCD) Conduct Disorder

ADHD

() ADHD

HCD

ADHD

()

ADHD

QT

()

ADHD

ADHD

ADHD

"(Atomoxetine)"

"

()

ADHD

(/ ± /)

() ADHD

(American Psychiatric Association
DSM-IV-TR ,2000)

()

()

Otk
ADHD

() Ratner

()

ADHD

Chi-square

Mann Whitney

(Fisher's exact test)


ANOVA ,two way)

(Repeated Measures Analysis of Variance

(T₃ T₀)

() (between subjects factor)

() (within subjects factor)



(% /)

)
(
(T₀)
DSM IV ADHD

ADHD
(Parent and Teacher ADHD Rating Scale)

(T₃) (T₂) (T₁)

ADHD

ADHD

()

()

mg

mg

()

mg

mg

] ()

ADHD

)

[

(

t

ADHD

(F= / df= / /
 Observed power=%) ()
) (F= / df= P> / (% /)

Observed power=%) ((% /) ADHD
 (F= / df= / / P> / / (% /)

ADHD

ADHD

(Mean±SD)	(Mean±SD)	ADHD	
/ ± /	/ ± /	° T ₀	
/ ± /	/ ± /	T ₁	
/ ± /	/ ± /	T ₂	
/ ± /	/ ± /	T ₃	
/ ± /	/ ± /	° T ₀	
/ ± /	/ ± /	T ₁	
/ ± /	/ ± /	T ₂	
/ ± /	/ ± /	T ₃	

(T₀)

ADHD

=T₁ =T₀
 =T₃ =T₂

% /

ADHD

% /

% /

% /

ADHD

(% /)

(% /)

(% /)

t
ADHD

ADHD

(Maunchly test)

ADHD

(P< /)

epsilon correction

()

/ P< / observed power=%)
) (F= / df= /

Observed power=%) ()
) (F= / df= P> /

Observed power=%) ()
 (F= / df= / / P> /

(Maunchly test)

ADHD

(P< /)

epsilon correction

()

P< / observed power = % /)

ADHD

ADHD

ADHD

REFERENCES

1. Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implication for management. *Ped Drugs* 2003;5: 741-50.
2. Hansen C, Weiss D, Last CG. ADHD boys in young adulthood: psychosocial adjustment. *Am Acad Child Adolesc Psychiatry* 1999;38:165-71.
3. Pliszka SR, McCracken JT, Mass JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. *Am Acad Child Adolesc Psychiatry* 1996;35:264-72.
4. Biederman J, Spenser T, Wilentz T. Evidence-based pharmacotherapy for attention deficit hyperactivity disorder. *Int Neuropsychopharmacol* 2004;7:77-7.
5. Weiss M, Weiss G. Attention deficit hyperactivity disorder .In: *Child and adolescent psychiatry*, Lewis M. ed. Baltimore : Willams and wilkins ;1996:645-70.
6. Greenhill LL. Pharmacological treatment of attention deficit disorder. *Psychiatr Clin North Am* 1992;15:1-25.

-
7. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffins S. Pharmacotherapy of attention deficit hyperactivity disorder across the life cycle. *Am Acad Child Adolesc Psychiatry* 1996;35:409-32.
 8. Banaschewski T, Roessener V, Dittman RW, Janardhanan Santosh, Rothenberger A. Non stimulant medications in the treatment of ADHD. *Eur Child Adolesc psychiatry* 2004;13(supple 1):1102-16.
 9. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: 1.Efficacy. *J Am Acad Child Adolesc Psychiatry* 1989;28:777-84.
 10. Labellarte MJ, Crosson JE, Riddle MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. *J Am Acad Child Adolesc Psychiatry* 2003;42: 642-50.
 11. Michelson D, Faries D, Wernicke J, Kesley D, TKendrick K, Sallee FR, Spencer T; Atomoxetine ADHD study group. Atomoxetin in the treatment of children and adolescent with attention deficit hyperactivity disorder: a randomized placebo-controlled dose-response study. *Pediatrics* 2001; 108(5): E83.
 12. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescent with attention deficit hyperactivity disorder : a randomized placebo-controlled study .*Am J Psychiatry* 2002; 159:1896-1901.
 13. Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention deficit hyperactivity disorder. *Arch Gen Psychiatry* 2002;59:649-56.
 14. Edwards DM, Pellizoni C, Breuel HP. Pharmacokinetics of reboxetine in healthy volunteers. single oral doses .linearity and plasma protein binding. *Biopharm Drug Dispos* 1995;16:443-60.
 15. Otko JE, Mercadante MT, Scahill L, Leckman JF. Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder [letter to the editor]; *J Child Adolesc Psychopharmacol* 2001; 11: 203-4.
 16. Ratner SH, Laor N, Bronstein Y, Weizman A, Toren P. Six week open-label reboxetine treatment in children and adolescents with attention deficit hyperactivity disorder. *Am Acad Child Adolesc Psychiatry* 2005;44:428-33.
 17. Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A. Reboxetine as an optimal treatment for hyperactive conduct disorder: a prospective open-label trial. *Child Adolesc Psychopharmacol* 2005;15:259-69.
 18. Dupaul GJ. Parent and teacher rating of ADHD symptoms: psychometric properties in a community based sample. *J Clinical child Psychology* 1991;20:245-53.
 19. Akhondzadeh SH, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children : a double blind and randomized trial. *Prog neuropsychopharmacol Bio Psychiatry* 2003; 27: 841-5.
 20. Wilens TE, Biederman J. The stimulants. *Psychiatr Clin North Am* 1992;90:191-222.

- /
-
- /
21. Tenreiro K. Methylphenidate-placebo: a trial for attention deficit disorders. *Int J Pharm Comp* 2001;5:21-2.
 22. Goldman L, Genel M, Bezman R, Slantez P. Diagnosis and treatment of attention deficit hyperactivity disorder in children and adolescents. *JAMA* 1998;279:1100-7.
 23. Klein RG, Landa B. Methylphenidate and growth in hyperactive children. *Arch Gen Psychiatry* 1988;45:1127-30.
 24. Pataki C, Carlson G. Side effects of methylphenidate and desipramine alone and in combination in children. *J Am Acad Child Adolesc Psychiatry* 1993;32:1065-82.
 25. Kehoe WA. Treatment of attention deficit hyperactivity disorder in children. *Ann Pharmacother* 2001;35:1130-4.

Archive of SID